Management of patients with chronic cerebrovascular pathology against the background of metabolic syndrome and diabetes mellitus
- 00:00:05
Introduction: Chronic cerebrovascular diseases and metabolic syndrome – relevance of the problem
- 00:01:26
Metabolic syndrome: pathogenesis and risk factors
- 00:07:27
Obesity and brain damage
- 00:13:22
Endothelial dysfunction and chronic cerebral ischemia
- 00:42:06
Mexidol: Efficacy data for cognitive impairment
Evgeniya Viktorovna Yekusheva , Doctor of Medical Sciences, Professor, Head of the Department of Nervous System Diseases and Neurorehabilitation at the Academy of Postgraduate Education of the Federal Scientific and Clinical Center of the Federal Medical and Biological Agency of Russia
Veronika Nikolaevna Shishkova - Doctor of Medical Sciences, Professor of the Department of Outpatient Therapy of the Faculty of Advanced Medical Studies, State Budgetary Healthcare Institution of the Moscow Region, Moscow Regional Scientific Research Institute named after M.F. Vladimirsky, Professor of the Department of Neuro- and Pathopsychology of the Institute of Psychology named after L.S. Vygotsky, Russian State University for the Humanities
Announcement:
Chronic cerebrovascular diseases, especially those associated with metabolic syndrome and diabetes, are one of the key challenges in modern medicine. In this video, leading specialists Evgeniya Viktorovna Yekusheva and Veronika Nikolaevna Shishkova discuss the pathogenesis, diagnosis, and modern approaches to treatment, paying particular attention to the role of obesity, insulin resistance, and cognitive impairment.
Main topics:
- Relevance: Metabolic syndrome (obesity, hypertension, diabetes) is a key risk factor for chronic brain damage. It affects one in four people in developed countries, and projections indicate a 50% increase in cases over the next 20 years.
- Pathogenesis: Systemic inflammation, insulin resistance, and endothelial dysfunction lead to microangiopathy, lacunar infarctions, and cognitive impairment. Neurological disorders are found in 95% of obese patients.
- The role of obesity: Abdominal obesity is a risk marker even with a normal BMI. A 1 cm increase in waist circumference increases the risk of cardiovascular complications.
- Cognitive impairment: the tip of the iceberg of cerebrovascular pathology. It manifests as a decline in memory, executive functions, and psychomotor speed, but often remains underdiagnosed.
- Therapy:
- Non-pharmacological methods: physical activity and lifestyle modification are critical.
- Pharmacological support: Mexidol is a drug with proven efficacy in improving cognitive function, reducing insulin resistance, and normalizing lipid profiles. Consistent therapy with the drug demonstrates sustained positive effects.
Key findings:
- Early diagnosis of metabolic disorders and cognitive deficits can slow the progression of diseases.
- An integrated approach (correction of risk factors + drug therapy) is the gold standard for patient care.
For whom: neurologists, therapists, cardiologists, endocrinologists and doctors of related specialties.
- 00:00:05
Introduction: Chronic cerebrovascular diseases and metabolic syndrome – relevance of the problem
- 00:01:26
Metabolic syndrome: pathogenesis and risk factors
- 00:07:27
Obesity and brain damage
- 00:13:22
Endothelial dysfunction and chronic cerebral ischemia
- 00:42:06
Mexidol: Efficacy data for cognitive impairment